Your session is about to expire
← Back to Search
Other
Reproxalap Ophthalmic Solution (0.25%) for Dry Eye Syndrome
Phase 2
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through trial completion, approximately four weeks
Awards & highlights
Study Summary
This study is evaluating whether a new eye drop can be used to treat dry eye disease.
Eligible Conditions
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through trial completion, approximately four weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through trial completion, approximately four weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adverse Event (AE) Query
Side effects data
From 2021 Phase 2 trial • 158 Patients • NCT049710314%
General disorders and administration site conditions
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vehicle
Reproxalap (0.25%)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Reproxalap Ophthalmic Solution (0.25%)Experimental Treatment1 Intervention
Single dose
Group II: Xiidra® (5% lifitegrast ophthalmic solution)Active Control1 Intervention
Single dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Reproxalap Ophthalmic Solution (0.25%)
2022
Completed Phase 3
~2690
Find a Location
Who is running the clinical trial?
Aldeyra Therapeutics, Inc.Lead Sponsor
29 Previous Clinical Trials
3,972 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger